维基百科中的医学内容
仅供参考,并
不能视作专业意见。如需获取医疗帮助或意见,请咨询专业人士。详见
医学声明。
IDX-184是一种抗病毒药物,开发用作NS5B RNA聚合酶抑制剂来治疗丙型肝炎。[1][2]尽管它在早期临床试验中显示出一定效果,但并未通过IIb期试验。[3]然而,该药物的研究仍在继续,并对一些新病毒(如兹卡病毒[4][5]、MERS[6]和SARS-CoV-2等冠状病毒[7][8])显示出一定的药物活性。
Quick Facts 法律规范状态, 法律规范 ...
IDX-184 |
|
法律规范 |
|
---|
|
S-[2-{[(2R,3R,4R,5R)-5-(2-amino-6-oxo-1H-purin-9-yl)-3,4-dihydroxy-4-methyloxolan-2-yl]methoxy-(benzylamino)phosphoryl}oxyethyl] 3-hydroxy-2,2-dimethylpropanethioate
|
CAS号 | 1036915-08-8 Y |
---|
PubChem CID | |
---|
ChemSpider | |
---|
UNII | |
---|
|
化学式 | C25H35N6O9PS |
---|
摩尔质量 | 626.6 |
---|
3D模型(JSmol) | |
---|
C[C@]1([C@@H]([C@H](O[C@H]1N2C=NC3=C2N=C(NC3=O)N)COP(=O)(NCC4=CC=CC=C4)OCCSC(=O)C(C)(C)CO)O)O
|
InChI=1S/C25H35N6O9PS/c1-24(2,13-32)22(35)42-10-9-38-41(37,28-11-15-7-5-4-6-8-15)39-12-16-18(33)25(3,36)21(40-16)31-14-27-17-19(31)29-23(26)30-20(17)34/h4-8,14,16,18,21,32-33,36H,9-13H2,1-3H3,(H,28,37)(H3,26,29,30,34)/t16-,18-,21-,25-,41?/m1/s1 Key:FGHMGRXAHIXTBM-TWFJNEQDSA-N
|
Close
Elfiky AA. Zika viral polymerase inhibition using anti-HCV drugs both in market and under clinical trials. J Med Virol. 2016 Dec;88(12):2044-2051. doi:10.1002/jmv.24678 PMID 27604059
Elfiky AA, Ismail AM. Molecular docking revealed the binding of nucleotide/side inhibitors to Zika viral polymerase solved structures. SAR QSAR Environ Res. 2018 May;29(5):409-418. doi:10.1080/1062936X.2018.1454981 PMID 29652194
Elfiky AA, Mahdy SM, Elshemey WM. Quantitative structure-activity relationship and molecular docking revealed a potency of anti-hepatitis C virus drugs against human corona viruses. J Med Virol. 2017 Jun;89(6):1040-1047. doi:10.1002/jmv.24736 PMID 27864902
Elfiky AA. Ribavirin, Remdesivir, Sofosbuvir, Galidesivir, and Tenofovir against SARS-CoV-2 RNA dependent RNA polymerase (RdRp): A molecular docking study. Life Sci. 2020 Mar 25:117592. doi:10.1016/j.lfs.2020.117592 PMID 32222463